Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-cycloserine augmented exposure therapy in patients with agoraphobia
2011-001398-19Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- May 2011
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of d-cycloserine in agoraphobia and panic disorder (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Panic and Agoraphobia Scale (PAS). Started May 2011; status: completed.
02
Drugs
d-cycloserine
03
Conditions
agoraphobiapanic disorder
Beyond the preview
Go deeper on 2011-001398-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001398-19.